Abstract:Opioid addiction is a chronic relapsing disorder in which drug-seeking behavior during abstinence can be provoked by exposure to a µ-opioid receptor (MOR) agonist or opioid-associated cues. Opioid self-administration behavior in laboratory subjects can be reinstated by priming with MOR agonists or agonist-related stimuli, providing a procedure suitable for relapse-related studies. The opioid antagonist naltrexone has been forwarded as a medication that can forestall relapse and, in an extended-release formulation, has demonstrated some treatment success. However, chronic naltrexone treatment has not been extensively investigated in nonhuman subjects and aspects of its pharmacology remain uncertain. For example, the relative effectiveness of naltrexone in reducing the priming strength of opioid agonists differing in efficacy is not well understood. Here, using intravenous self-administration and warm-water tail withdrawal procedures, we investigated changes in the direct reinforcing effects of oxycodone and in the priming strength and antinociceptive effects of opioid agonists in squirrel monkeys (n = 4) during chronic treatment with naltrexone (0.2 mg/kg/d). Results show that naltrexone produced: 1) a 10-fold rightward shift in the dose-response function for the reinforcing effects of oxycodone, and 2) in reinstatement and antinociception experiments, comparable rightward shifts in the dose-response functions for higher-efficacy MOR agonists (methadone, heroin, and oxycodone) but rightward and downward shifts in the dose-response functions for lower-efficacy MOR agonists (buprenorphine, nalbuphine, and butorphanol). These results suggest that, although chronic naltrexone should be effective in forestalling relapse following exposure to lower- and higher-efficacy agonists, the inability of lower-efficacy agonists to surmount naltrexone antagonism may complicate the prescription of opioids for pain. SIGNIFICANCE STATEMENT: Although naltrexone is commonly used in the treatment of opioid use disorder, its ability to reduce the priming strength of opioid agonists has not been extensively investigated. This study shows that chronic naltrexone treatment induces rightward shifts in the reinstatement and antinociceptive properties of higher efficacy opioid agonists, but rightward and downward shifts for lower efficacy opioid agonists, suggesting lower efficacy agonists may not be able to surmount naltrexone-induced antagonism of these two effects, and perhaps naltrexone offers greater protection against lower efficacy agonists.

Successive Treatment With Naltrexone Induces Epithelial-Mesenchymal Transition And Facilitates The Malignant Biological Behaviors Of Bladder Cancer Cells

Effect and Mechanism of Opioid Receptor Antagonist on Allograft Rejection

Low-dose naltrexone inhibits the epithelial-mesenchymal transition of cervical cancer cells in vitro and effects indirectly on tumor-associated macrophages in vivo

Low-Dose Naltrexone as an Adjuvant in Combined Anticancer Therapy

Sodium Butyrate Inhibits Migration and Induces AMPK-mTOR Pathway-Dependent Autophagy and ROS-mediated Apoptosis Via the Mir-139-5p/bmi-1 Axis in Human Bladder Cancer Cells.

Major clinical evidence on the use of low-dose naltrexone in the treatment of cancer: a systematic review

Nitroxoline Inhibits Bladder Cancer Progression by Reversing EMT Process and Enhancing Anti-Tumor Immunity

Epithelial-Mesenchymal Transition Induced By Gro-Alpha-Cxcr2 Promotes Bladder Cancer Recurrence After Intravesical Chemotherapy

The Effects of Chronic Naltrexone on Reinstatement of Opioid-Induced Drug-Seeking Behavior and Antinociception

Simultaneous Activation of K-ras and NRF2 Induce Pancreatic Atrophy

Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer

Twisted Epithelial-to-mesenchymal Transition Promotes Progression of Surviving Bladder Cancer T24 Cells with Htert-Dysfunction.

Effects of Naltrexone on Expression of Lipid Metabolism-Related Proteins in Liver Steatosis Induced by Endoplasmic Reticulum Stress in Mice

Therapeutic Potential of Regorafenib in Cisplatin-Resistant Bladder Cancer with High Epithelial–Mesenchymal Transition and Stemness Properties

RNA Interference-Mediated Vascular Endothelial Growth Factor-C Reduction Suppresses Malignant Progression and Enhances Mitomycin C Sensitivity of Bladder Cancer T24 Cells

LINC01451 drives epithelial-mesenchymal transition and progression in bladder cancer cells via LIN28/TGF-β/Smad pathway

Lentivirus-mediated NDRG2 gene overexpression inhibits radioresistance of bladder cancer cells

Naltrexone accelerated oral traumatic ulcer healing and downregulated TLR-4/NF-kB pathway in Wistar rats

The lncRNA DLX6-AS1 promoted cell proliferation, invasion, migration and epithelial-to-mesenchymal transition in bladder cancer via modulating Wnt/β-catenin signaling pathway

Nitroxoline Suppresses Metastasis in Bladder Cancer Via EGR1/circNDRG1/miR-520h/smad7/EMT Signaling Pathway.

Long Non‑coding RNA 00858 Knockdown Alleviates Bladder Cancer Via Regulation of the Mir‑3064‑5p/ctgf Axis.